Featured Research

from universities, journals, and other organizations

Lupus Patients Are In Remission Two Years After High-Dose Chemotherapy And Stem-Cell Transplantation

Date:
August 25, 2000
Source:
Northwestern University
Summary:
A combination of high-dose chemotherapy and stem-cell transplantation could be an effective treatment for severe lupus, a serious autoimmune disorder affecting thousands of young and middle-aged people yearly, most of them female.

CHICAGO --- A combination of high-dose chemotherapy and stem-cell transplantation could be an effective treatment for severe lupus, a serious autoimmune disorder affecting thousands of young and middle-aged people yearly, most of them female.

Related Articles


As reported in the Aug. 25 issue of The Lancet, Ann Traynor, M.D., and colleagues from Northwestern University Medical School evaluated the safety and efficacy of high-dose immune suppression and stem-cell transplantation in patients with lupus.

The researchers found that, at an average follow-up of two years after treatment, all patients were free from signs of active lupus, and their kidney, heart, lung and immune system function had become normal.

Stem cells are "mother cells," or progenitors, that have the capacity to expand and differentiate into many types of cells, including infection-fighting T and B cells.

From 1996, the researchers selected seven patients with aggressive lupus that persisted despite the use of cyclophosphamide, a potent immunosuppressant drug.

The patients underwent high-dose immune suppression and received infusions of stem cells that they had donated before receiving immunosuppressive therapy. The patients' circulating white blood cells were analyzed before and after transplantation.

"What is exciting about this observation is that it appears that the immune system can correct its errors if early stem cells are allowed to mature as naive cells in a 'neutral' environment," Traynor said.

"This new generation of immune cells is not destined to repeat the ruinous errors of the prior generations. Our observation may have implications for the treatment of many immune disorders, including multiple sclerosis, myasthenia gravis, and even some types of cancers," Traynor said.

Several hundred thousand individuals in the United States have lupus; between 10 percent and 15 percent of these patients are expected to die within 10 years of diagnosis.

Lupus is an autoimmune inflammatory disease that results when disease-fighting cells in the body create antibodies directed against its own cells and tissues. The immune cells attack the individual's own organs in the manner that immune cells normally reject only foreign organisms, tumors or grafts.

This process can lead to destruction of the normal kidney, heart, brain, spine and lung tissue. When uncontrolled, it can lead to death.

Current therapies for lupus include steroids and immunosuppressive medications including chemotherapy. Patients with lupus who experience persistent multi-organ dysfunction despite standard doses of intravenous cyclophosphamide represent a subset at high risk for early death.

Traynor is an assistant professor of medicine at Northwestern University Medical School and a physician/researcher in the bone marrow transplantation program at Northwestern Memorial Hospital. Her co-authors at Northwestern were James Schroeder, M.D., assistant professor of medicine; Robert M. Rosa, M.D., professor of medicine; Dong Cheng; Jakub Stefka; Salim Majais; Steven Baker, M.D., assistant professor of medicine; and Richard K. Burt, M.D., assistant professor of medicine and director of the allogeneic bone marrow transplantation program at Northwestern Memorial Hospital. Traynor and Burt also are members of The Robert H. Lurie Comprehensive Cancer Center of Northwestern University.


Story Source:

The above story is based on materials provided by Northwestern University. Note: Materials may be edited for content and length.


Cite This Page:

Northwestern University. "Lupus Patients Are In Remission Two Years After High-Dose Chemotherapy And Stem-Cell Transplantation." ScienceDaily. ScienceDaily, 25 August 2000. <www.sciencedaily.com/releases/2000/08/000825082226.htm>.
Northwestern University. (2000, August 25). Lupus Patients Are In Remission Two Years After High-Dose Chemotherapy And Stem-Cell Transplantation. ScienceDaily. Retrieved December 19, 2014 from www.sciencedaily.com/releases/2000/08/000825082226.htm
Northwestern University. "Lupus Patients Are In Remission Two Years After High-Dose Chemotherapy And Stem-Cell Transplantation." ScienceDaily. www.sciencedaily.com/releases/2000/08/000825082226.htm (accessed December 19, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, December 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins